Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Mallinckrodt
Colorcon
Chinese Patent Office
McKinsey
Medtronic

Generated: August 24, 2019

DrugPatentWatch Database Preview

Claims for Patent: 6,720,153

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,720,153
Title: Luciferase reporter bioassay of parathyroid hormone compounds
Abstract:This invention is directed to a bioassay for determining the functionality of parathyroid hormone compounds. More particularly, this invention is directed to a bioassay wherein the compound to be tested is added to a culture of parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple c-AMP responsive elements.
Inventor(s): Labaudiniere; Richard F. (Collegeville, PA), Yu; Kin T. (Limerick, PA), Crumley; Gregg R. (Philadelphia, PA), Morse; Clarence C. (Royersford, PA)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/387,176
Patent Claims:1. A method for determining the functionality of a parathyroid hormone compound, the method comprising (a) adding the compound to a culture of parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple cAMP responsive elements, and then measuring the expression of the reporter gene; and (b) comparing the measured expression of step (a) with the measured expression of the reporter gene in a control culture comprising: (i) the parathyroid hormone receptor expressing cells bearing the reporter gene under the transcriptional control of multiple cAMP response elements, and a parathyroid hormone, a parathyroid hormone-related protein, a parathyroid receptor agonist, or a combination thereof, or (ii) the parathyroid hormone receptor expressing cells bearing a reporter gene under the transcriptional control of multiple cAMP responsive elements, in the absence of the parathyroid hormone compound, wherein a difference between the measured expression of step (a) and the measured expression of the control culture is indicative of the functionality of the parathyroid hormone compound, and wherein the number of cAMP responsive elements is greater than about 10.

2. The method according to claim 1, wherein the number of cAMP responsive elements is about 16.

3. The method according to claim 2, wherein the cells are mammalian cells.

4. The method according to claim 2, wherein the cells comprise a heterologous nucleic acid encoding the parathyroid hormone receptor.

5. The method according to claim 2, wherein the reporter gene encodes a protein selected from the group consisting of .beta.-galactosidase, chloramphenicol acetyltransferase, .beta.-glucuronidase, and luciferase.

6. The method according to claim 5, wherein the reporter gene encodes luciferase.

7. The method according to claim 2, wherein the parathyroid hormone receptor is human parathyroid hormone receptor.

Details for Patent 6,720,153

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23 ➤ Sign Up Aventis Pharmaceuticals Inc. (Bridgewater, NJ) 2018-09-04 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23 ➤ Sign Up Aventis Pharmaceuticals Inc. (Bridgewater, NJ) 2018-09-04 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23 ➤ Sign Up Aventis Pharmaceuticals Inc. (Bridgewater, NJ) 2018-09-04 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23 ➤ Sign Up Aventis Pharmaceuticals Inc. (Bridgewater, NJ) 2018-09-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
AstraZeneca
Moodys
McKinsey
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.